Table 1.
Some recent promising therapies on intestinal fibrosis.
| Methods | Predominant compounds | Reference |
|---|---|---|
| Regulating ECM | Sulfasalazine | 60 |
| Pirfenidone | 61 | |
| Regulating cytokines and chemokines | Peroxisome proliferator-activated receptor-gamma (PPAR-γ) | 62 |
| Paeonia decoction | 63 | |
| IL36R | 65 | |
| Anti-Tl1a antibody or an IgG isotype control | 66 | |
| Naringenin | 68 | |
| Colitis 1 formula and mesalazine | 69 | |
| Targeting TGF-β | Calycosin (CA) | 74 |
| Pre-gum arabic (GA) | 75 | |
| Vitamin D | 76 | |
| Adiponectin | 77 | |
| baicalin | 78 | |
| Regulating EMT | PPAR-γ modulator | 82 |
| halofuginone | 83 | |
| recombinant human bone morphogenetic protein-7 (rhBMP-7) | 84 | |
| Regulating the differentiation of fibroblast to myofibroblast | proteoglycans and THY1 | 85,86 |
| AXL | 87 | |
| miR-29 | 89–91 |